The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Concomitant antibiotics (ATBs) use and survival outcomes in patients (pts) with muscle-invasive bladder cancer (MIBC) treated with neoadjuvant pembrolizumab (PURE-01 study).
 
Daniele Raggi
No Relationships to Disclose
 
Marco Bandini
Travel, Accommodations, Expenses - ASCO
 
Filippo Pederzoli
No Relationships to Disclose
 
Patrizia Giannatempo
No Relationships to Disclose
 
Laura Marandino
Travel, Accommodations, Expenses - Sanofi
 
Giuseppe Basile
No Relationships to Disclose
 
Andrea Gallina
No Relationships to Disclose
 
Alberto Briganti
Consulting or Advisory Role - Astellas Pharma; Ferring; Janssen-Cilag; MDxHealth; OPKO Health
Speakers' Bureau - Astellas Pharma
Research Funding - Merck Sharp & Dohme; Sandoz-Novartis
 
Francesco Montorsi
No Relationships to Disclose
 
Andrea Necchi
Employment - Bayer (I)
Stock and Other Ownership Interests - Bayer (I)
Honoraria - AstraZeneca; Bristol-Myers Squibb; Foundation Medicine; Janssen; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ferring; GlaxoSmithKline; Incyte; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche; Seattle Genetics/Astellas
Research Funding - AstraZeneca (Inst); Ipsen; Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche
Other Relationship - Bayer (I)